To elucidate the mechanistic contribution of cellular senescence to cynaroside’s therapeutic efficacy in NASH-T2DM comorbidity, we quantitatively assessed hepatic senescence markers via SA-β-gal staining and senescence regulators p53 and p21. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatohepatitis.